Table 2

Prediction of 6-month SDAI outcome by predefined response criteria at 3 months

Response levels observed at 3 months		Treatment target at 6 months: SDAI remission				Treatment target at 6 months: SDAI LDA
Definition	% (n/N)	Sens	Spec	LR+	LR−	Sens	Spec	LR+	LR−
SDAI 50%	46.6% (750/1610)	0.84	0.58	2.01	0.27	0.66	0.71	2.26	0.48
SDAI 70%	23.7% (382/1610)	0.63	0.81	3.30	0.46	0.39	0.89	3.59	0.69
SDAI 85%	8.7% (140/1610)	0.36	0.95	6.56	0.68	0.16	0.98	6.45	0.86
CDAI 50%	45.7% (735/1610)	0.84	0.59	2.06	0.26	0.66	0.72	2.33	0.48
CDAI 70%	24.3% (391/1610)	0.61	0.80	3.07	0.49	0.38	0.88	3.22	0.70
CDAI 85%	9.9% (160/1610)	0.36	0.93	5.36	0.68	0.18	0.97	6.15	0.85
EULAR moderate*	61.1% (984/1610)	0.78	0.41	1.32	0.53	0.74	0.50	1.47	0.53
EULAR good	25.6% (412/1610)	0.61	0.79	2.90	0.49	0.42	0.89	3.70	0.66
ACR20	44.4% (715/1610)	0.66	0.58	1.57	0.59	0.55	0.65	1.54	0.70
ACR50	23.6% (380/1610)	0.54	0.80	2.71	0.57	0.36	0.87	2.76	0.74
ACR70	9.5% (153/1610)	0.32	0.93	4.63	0.73	0.16	0.96	4.30	0.87

*EULAR moderate/good response.
ACR, American College of Rheumatology; CDAI, Clinical Disease Activity Index; EULAR, European League Against Rheumatism; LDA, low disease activity; LR−, negative likelihood ratio; LR+, positive likelihood ratio; SDAI, Simplified Disease Activity Index; Sens, sensitivity; Spec, specificity.